2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-175275
    10-Butyl Ether Minocycline 488815-65-2 98%
    10-Butyl Ether Minocycline (BEM), a Minocycline (HY-17412A) derivative, is an MMP-8 and MMP-9 inhibitor with IC50s of 69.4 µM and 47.0 µM, respectively. 10-Butyl Ether Minocycline suppresses LPS (HY-D1056)-induced microglial activation. 10-Butyl Ether Minocycline inhibits VEGF-induced endothelial cell migration and L-Glutamine (HY-N0390)-induced ROS levels. 10-Butyl Ether Minocycline significantly reduces alcohol consumption in the Chronic Intermittent Ethanol (CIE) mouse model of alcohol dependence. 10-Butyl Ether Minocycline can be used for the study of neuroimmune-inflammatory diseases and Alcohol use disorder (AUD).
    10-Butyl Ether Minocycline
  • HY-175277
    PIM1-IN-8
    PIM1-IN-8 is a PIM1/p65 pathway inhibitor. PIM1-IN-8 suppresses the expression of α-SMA and collagen I in activated fibroblasts and blocks TGF-β induced migration. PIM1-IN-8 alleviates pulmonary fibrosis in a Bleomycin (BLM) (HY-17565A)-induced pulmonary fibrosis mice model. PIM1-IN-8 can be used for the study of idiopathic pulmonary fibrosis (IPF).
    PIM1-IN-8
  • HY-175278
    BAL-1516
    BAL-1516 is a brain-penetrant and highly selective NLRP3 inhibitor (IC50=14.2 nM). BAL-1516 significantly suppresses IL-1β and IL-18 release in microglial neuroinflammation models (IC50=11-59 nM). BAL-1516 is promising for research of neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and systemic inflammatory disorders.
    BAL-1516
  • HY-175286
    α4β1 antagonist-1 98%
    α4β1 antagonist-1 (Compound 4) is a highly selective α4β1 integrin antagonist (IC50=15 nM). α4β1 antagonist-1 inhibits integrin-mediated cell adhesion and ERK1/2 signaling activation. α4β1 antagonist-1 also exhibits partial agonism toward αMβ2 integrin (EC50=23 nM). α4β1 antagonist-1 is promising for research of chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancers.
    α4β1 antagonist-1
  • HY-175288
    αMβ2 integrin agonist-1 98%
    αMβ2 integrin agonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory activity (EC50=1.4 nM). αMβ2 integrin agonist-1 activates integrin-mediated cell adhesion and JNK/ERK signaling. αMβ2 integrin agonist-1 induces tumor-associated macrophage repolarization and enhances antitumor T-cell immune responses. αMβ2 integrin agonist-1 is promising for research of cancers and chronic inflammatory diseases (e.g., pancreatic cancer, rheumatoid arthritis).
    αMβ2 integrin agonist-1
  • HY-175306
    GPR183 inverse agonist-1 2380033-51-0 98%
    GPR183 inverse agonist-1 (Compound 78) is a GPR183 inverse agonist. GPR183 inverse agonist-1 inhibits the GPR183-mediated Gi activation and β-arrestin2 recruitment, and blocks PBMC migration. GPR183 inverse agonist-1 can be used for inflammatory, autoimmune and neoplastic disorders research.
    GPR183 inverse agonist-1
  • HY-175344
    TMP1 98%
    TMP1 is an orally active bispecific inhibitor of M pro (IC50 = 312.5 nM)/TMPRSS2 (IC50 = 1.28 μM, KD = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research.
    TMP1
  • HY-175348
    XB2M54 1467165-30-5 98%
    XB2M54 is a selective XIAP antagonist. XB2M54 inhibits NOD2-mediated inflammatory signaling. XB2M54 is an E3 ligase ligand. XB2M54 can be used for synthesis of PROTAC ERα Degrader-1 (HY-112098).
    XB2M54
  • HY-175365
    GCS-12–6
    GCS-12–6 is a potent Th2-selective NKT cell agonist targeting CD1d protein. GCS-12–6 is promising for research of autoimmune diseases (e.g., inflammatory bowel disease, multiple sclerosis).
    GCS-12–6
  • HY-175369
    PI3Kδ-IN-25 98%
    PI3Kδ-IN-25 is an orally active selective PI3Kδ inhibitor (IC50 = 2.1 nM). PI3Kδ-IN-25 has IC50s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers.
    PI3Kδ-IN-25
  • HY-175390
    6-Thioguanosine-5'-O-diphosphate sodium
    6-Thioguanosine-5'-O-diphosphate sodium (6-Thio-GDP sodium) (TGDP sodium) is an active metabolite of 6-Mercaptopurine (HY-13677). 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.
    6-Thioguanosine-5'-O-diphosphate sodium
  • HY-175392
    PROTAC sEH-degrader-3 3093413-94-3 98%
    PROTAC sEH-degrader-3 (Compound 1a) is a targeted sEH PROTAC degrader that can selectively degrade sEH in the cytosol without affecting sEH in peroxisomes. PROTAC sEH-degrader-3 degrades sEH through a CRBN-dependent lysosomal pathway rather than the proteasome, with an IC50 of 0.8 nM against hsEH. PROTAC sEH-degrader-3 can inhibit endoplasmic reticulum stress and can be used in the research of inflammation, metabolic diseases, and other diseases related to endoplasmic reticulum stress. (Pink: sEH inhibitor (HY-114266); Black: Linker (HY-W008352); Blue: E3 Ligase Ligand (HY-14658)).
    PROTAC sEH-degrader-3
  • HY-175402
    (S)-5-Hydroxyequol 276669-86-4 98%
    (S)-5-Hydroxyequol is a soy isoflavone metabolite with antioxidant and anti-inflammatory properties.
    (S)-5-Hydroxyequol
  • HY-175429
    p38 MAPK-IN-7 165806-50-8
    p38 MAPK-IN-7 (Compound 2) is an orally active, potent and selective p38 MAP kinase inhibitor (IC50=170 nM). p38 MAPK-IN-7 is promising for research of inflammatory diseases such as rheumatoid arthritis and septic shock.
    p38 MAPK-IN-7
  • HY-175430
    TNF-α-IN-26 165806-63-3
    TNF-α-IN-26 (Compound 18) is a TNF-α inhibitor with an IC50 of 0.10  μM for CSBP ligands. TNF-α-IN-26 inhibits LPS (HY-D1056)-stimulated TNF production in mice model. TNF-α-IN-26 can be used for inflammatory diseases research.
    TNF-α-IN-26
  • HY-175431
    p38 MAPK-IN-8 208182-49-4 98%
    p38 MAPK-IN-8 (Compound 8) is an orally active, potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. p38 MAPK-IN-8 is promising for research of inflammatory responses, autoimmune diseases, and cancer.
    p38 MAPK-IN-8
  • HY-175432
    p38 MAPK-IN-9 180869-17-4
    p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC50 value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD).
    p38 MAPK-IN-9
  • HY-175433
    p38 MAPK-IN-10 340041-97-6
    p38 MAPK-IN-10 (Compound 4) is an orally active and potent p38 MAP kinase inhibitor (IC50=570 nM). p38 MAPK-IN-10 is promising for research of chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.
    p38 MAPK-IN-10
  • HY-175437
    MRT-7612
    MRT-7612 (Compound 4) is a cereblon-based tyrosine kinases molecular glue degrader. MRT-7612 significantly induces HCK and LYN degradation, with week efficacy on LCK. MRT-7612 can be used for cancers like chronic myeloid leukemia, autoimmune and chronic inflammatory diseases research.
    MRT-7612
  • HY-175459
    PROTAC FAK degrader 3 98%
    PROTAC FAK degrader 3 is a selective FAK PROTAC degrader (DC50 = 1.08 nM). PROTAC FAK degrader 3 induces FAK degradation dependent on the ubiquitin-proteasome system and its binding to FAK and CRBN. PROTAC FAK degrader 3 upregulates MHC-I gene transcription and tumor cell surface expression by inhibiting the non-catalytic activity of FAK, leading to increased antigen presentation and activation of cytotoxic CD8 T cells. PROTAC FAK degrader 3 enhances in vivo anti-tumor activity by promoting MHC-I expression and enhancing T cell activation. PROTAC FAK degrader 3 can be used in cancer research targeting FAK degradation in ovarian cancer, hepatocellular carcinoma, and other cancers. (Pink: FAK-IN-3:HY-143407, Blue: Thalidomide-4-OH:HY-103596, Blue + Black: FAK ligand-3: HY-W939883, Black: Linker).
    PROTAC FAK degrader 3
Cat. No. Product Name / Synonyms Application Reactivity